Original Research Article

Assessment of vibratory QST abnormality in diabetic patients with special correlation to duration of diabetes

Kaushik Saha¹, Dipa Saha²*

¹Department of Medicine, ²Department of Physiology, KPC Medical College and Hospital, Jadavpur, Kolkata, West Bengal, India

Received: 10 March 2020
Accepted: 23 March 2020

*Correspondence:
Dr. Dipa Saha,
E-mail: drkaushikmedped@gmail.com

ABSTRACT

Background: Peripheral Neuropathy is one of the common microvascular complications in diabetes mellitus affecting both large and small nerve fibres. In present study we have assessed the impairment of vibration perception threshold (VPT) QST that enables evaluation of affection of large myelinated (Aα and Aβ) fibres.

Methods: Authors used Biothesiometer in our study that served a satisfactory tool for quantitating vibratory sense. In our study 120 diabetic patients between 30 to 60 yrs age group with duration of illness ≤10 yrs, 10-20 years and more than 20 years were subjected to Vibratory QST by instrument (Vibrotherm Dx) at several specific points of feet.

Results: The result observed is, 73.2% (n=22) diabetics with clinical neuropathy show impairment of vibration sense, while 60% of diabetic patients without clinical neuropathy also show impairment of vibration sense. Result suggests involvement of nerve fibres in a subclinical stage in diabetic patients. Relation between vibratory QST and duration of diabetes is also established, Chi-square trend test is done and it shows there is positive trend with duration of diabetes and it is statistically significant p≤0.001.

Conclusions: This study suggests that Vibratory QST should be carried out in every diabetic patient irrespective of clinical neuropathy and duration of diabetes, for early detection, progression & institution of therapy.

Keywords: Diabetic peripheral neuropathy, QST, Vibration perception threshold

INTRODUCTION

Diabetes is a chronic progressive disorder with increasing worldwide prevalence and is of much concerned because of its devastating complications. Between this, nervous system is most frequently affected.¹ Diabetes affects both large and small myelinated fibres and unmyelinated nerve fibres as well.² Clinical symptom varies widely in peripheral neuropathy due to diabetes.

In majority of cases sensory symptoms predominate and abnormality may be in proprioceptive or exteroceptive sensory system.³ Vibratory QST have added much to early diagnosis of peripheral neuropathy. Previous study showed that in mild to moderate diabetic neuropathy, the Biothesiometer VPT serves excellent reliability and serves as an appropriate screening tool.⁴ Likely hood of neuropathy must be tested with superficial pain sensation testing or vibratory testing.⁵ Vibratory QST evaluates affection of peripheral nerve in a quantifiable manner.⁶ However contradictory report regarding Vibratory QST testing in peripheral neuropathy has been reported. One study stated that in diabetes patients without clinical evidence of neuropathy there were no correlations between vibratory threshold and thermal threshold.⁷ VPT testing in diabetic neuropathy had done by many authors.⁸⁻⁹ But very few reports have been documented in our country.

DOI: http://dx.doi.org/10.18203/2349-3933.ija20201506
Therefore, this study is done to evaluate if Vibratory QST testing can be applied in our country for early diagnosis of diabetic peripheral neuropathy. The use of Biothesiometer has served a satisfactory tool for quantifying vibratory sense.9

More over one study showed, very recently Biothesiometer QST study is being used for diagnosis of neuropathy especially of small and large fibre, which increases the sensitivity of detecting neuropathy from 30-90% or more.10

METHODS

The studies on Vibratory QST were conducted in Department of Medicine, K P C Medical College, Kolkata with help of instrument (Neuropathy Analyser - Vibrotherm Dx) (vibration and thermal perception threshold detector).

In this study we have taken average of 6 specific points in both feet:

- Great toe
- 1st metatarsal
- 3rd metatarsal
- 5th metatarsal
- Instep
- Heel

![Figure 1: Six specific points of both feet for VPT.](image)

Procedure - first probe was applied to patient’s hand to explain the feel of vibration clearly. Then patient is asked to concentrate on feet and tell as soon as he starts feeling the vibration and value is noted. Quantification of vibratory sense was detected in 120 diabetic patients of which 60 had clinical neuropathy and 60 had no clinical neuropathy. During recording, the voltage was increased from 0 to 50 volts. The instrument specific normative data found after studying 100 controls are as follows:

- Normal - upto 15 volt
- Grade I - 16 to 25Volt
- Grade II - >25 volt.

Inclusion criteria

- Mentally alert and conscious subjects with full knowledge about the matter participated in the study.
- Among 120 subjects of T2DM were included who were diagnosed at least two years back and with or without ongoing treatment of which 60 had clinical neuropathy and 60 had no clinical neuropathy.

Exclusion criteria

- Patients with other comorbidities like cancer, cirrhosis of liver, multi organ failure, and chronic kidney disease etc. were excluded from the study,
- Those below 30 years of age and above 70 years of age,
- Pregnant women were not included in the study,
- T1 DM patient.

Statistics

Chi-square test has been applied between the parameters.

RESULTS

The observation of results as in Table 1 showed that, among the diabetic patients with clinical neuropathy 73.2% had abnormal VPT and, 26.6% and 46.6% shows grade I and grade II severity respectively, whereas, 26.6% show normal VPT. Interestingly even in diabetic patient without clinical neuropathy, 60% show grade I severity with VPT testing.

So, maximum patients with clinical neuropathy show grade II severity with vibration perception threshold.

| Grade of VPT | Clinical symptom | Subclinical | Total |
|--------------|------------------|-------------|-------|
| Normal       | 16               | 24          | 40    |
| Abnormal     | 44               | 36          | 80    |
| Total        | 60               | 60          | 120   |

Table 1: Frequency distribution of abnormal and normal Vibratory QST in clinical and subclinical cases.
It is observed from the table 2 that 24 (40%) patients having no clinical neuropathy belong to normal grade of VPT against 16 (26.6%) patients having clinical neuropathy. 16 patients (26.6 %) with clinical neuropathy develop grade I VPT, while 36 (60%) patients with no clinical neuropathy also have grade I severity. Whereas, 24 (46.6%) patients with clinical neuropathy were identified as grade II sufferer and no patient of grade II abnormality seen in subclinical neuropathy. Taking into consideration of 2 groups of patient with normal and abnormal severity, chi square test is done. It is observed that chi-square = 1.2 (P> 0.05) i.e., there is no significant difference between the symptomatic and asymptomatic cases.

In this study, we found that 80 cases of Vibratory QST abnormality is distributed as 6.25%, 41.25%, 52.5% when duration of diabetes is less than 10 years, 10 to 20 years and more than 20 years respectively (Table 3). Chi-square trend test has been done and it shows that there is a positive trend with duration of diabetes and it is statistically significant with (p< 0.001).

**DISCUSSION**

Most of the clinical neuropathic patients showed abnormal VPT either grade I or grade II, but 16 patients out of 60 do not have any abnormal VPT. In present study the result show diverse values of Vibratory QST testing. Reason may be that VPT testing is more of subjective in nature. Similar findings have also been reported. Among the diabetic neuropathic patients, 28 had grade II abnormality and 16 had grade I abnormality. The reason for different grades of neuropathy may be due to variable duration of illness. The observation of Vibratory QST testing in diabetic patients without clinical neuropathy showed grade I severity in 60% patients.

It means that certainly there is affection of nerve fibres in subclinical state without any symptoms. Therefore, Vibratory QST testing to find out the probability of developing neuropathy should assess every subclinical cases of neuropathy in diabetes. Van Deusen RW et al, stated that in mild to moderate diabetic neuropathy the biothesiometer Vibratory QST serves excellent reliability and serves as an appropriate screening tool. Therefore, it is better to have therapy should be instituted in these subclinical cases of neuropathy on the basis of Vibratory QST abnormality to prevent disease progression along with glycemic control. This study demonstrates that Vibratory QST should assess all cases of diabetic patients irrespective of clinical symptoms of neuropathy for early diagnosis and treatment. Further analysis shows 11.3% (5/41) with duration less than 10 years, 90.24% (37/41) of 10-20 years and 100% (42/42) of more than 20 years had abnormal Vibratory QST. Statistically there is a positive trend with duration of diabetes and Vibratory QST abnormality (Table 3). So, it is obvious that Vibratory QST is more sensitive for all stages of DM and more so in early and median duration cases.

**ACKNOWLEDGEMENTS**

Authors would like to thank Department of Medicine and Department of Physiology, KPC Medical College, Jadavpur, Kolkata.

**Funding:** No funding sources

**Conflict of interest:** None declared

**Ethical approval:** The study was approved of KPC Medical College

**REFERENCES**

1. Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort. Neurol, 1993;43:817-24.
2. Young MJ, Boulton AJM, MacLeod AF, Williams DRR, Sonksen PH. A multicenter study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetol. 1993;36:150-4.
3. Shy ME, Frohman EM, SOYT, Arezzo JC. QST report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurol. 2003;60(6):898-904.
4. Van Deusen RW, Sanchez MM, Derr JA, Becker MB, Ulbrecht JS, Cavanagh PR. Vibration perception threshold testing in patients with diabetic neuropathy: ceiling effects and reliability. Diabet Med. 2001;18(6):469-75.
5. Perkins BA, Olaleye D, Zinman B. Simple screening test for peripheral neuropathy in the diabetes clinic, Diabetes care. 2001;24(2):250-6.
6. Vinik EJ, Hayes RP, Oglesby A, Bastyr E, Barlow P, Ford-Molvik SL, et al. The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and neuropathy.

---

Table 3: Relation between duration of diabetes and QST.

| Duration of DM/ QST | < 10 years | 10 - 20 years | > 20 years | Total |
|---------------------|------------|--------------|------------|-------|
| QST (Normal)        | 36 (80%)   | 4 (8%)       | 0 (0%)     | 40 (100%) |
| QST (Abnormal)      | 5 (6.25%)  | 33 (41.25%)  | 42 (52.5%) | 80 (100%) |
| Total               | 41         | 37           | 42         | 120    |
diabetic neuropathy. Diabetes Technol Ther. 2005;7:497-508.

7. Gelber DA, Pfeifer MA, Broadstone VL, Munster EW, Peterson M, Arezzo JC et al. Components of variance for vibratory and thermal threshold testing in normal and diabetic subjects. J Diabetes Complications. 1995;9(3):170-6.

8. Sorensen, Lea BHSC, Molyneaux, Lynda RN; QST VIBRATORY of large nerve fibres function is a useful test to detect presence of neuropathy very early. Clin J Pain. 2006;22(3):261-5.

9. Jamal GA, Hansen S, Weir AI, Ballantyne JP. QST added more accuracy, sensitivity and specificity in diagnosing diabetic neuropathy. The neurophysiologic investigation of small fibre neuropathies. Muscle Nerve. 1987;10:537-45.

10. Coppini DV, Young PJ, Weng C, Macleod AF, Sonksen PH. Outcome on diabetic foot complications in relation to clinical examination and quantitative sensory testing: a case control study. Diabet Med. 1998;15(9):756-71.

Cite this article as: Saha K, Saha D. Assessment of vibratory QST abnormality in diabetic patients with special correlation to duration of diabetes. Int J Adv Med 2020;7:750-3.